

Josefine Persson,¹ Michael Pollack,² Hayley D. Germack,³ Malin Fageras,⁴ Timothy L. Barnes,⁵ Meredith C. McCormack⁶

¹Global Pricing and Market Access, BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden; ²Global Respiratory Medical Evidence, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; ³US Evidence, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; ⁴Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; ⁵Optum Life Sciences, Eden Prairie, MN, USA; ⁶Division of Pulmonary & Critical Care Medicine, Johns Hopkins Medicine, Baltimore, MD, USA

Why did we perform this research?

- Many patients with chronic obstructive pulmonary disease (COPD) remain at high risk of exacerbations and mortality despite receiving dual or triple inhaled therapy (DT/TT).
- Evaluation of the long-term outcomes for this patient population is needed to inform clinical care and guide future research.
- This study evaluates the 3-year occurrence of exacerbations and mortality among high-risk patients with COPD who are receiving DT/TT.

What did we find?

Overall cohort: N=16,968

Mean (SD) age
62.6 (10.2) years

37% 63%

Mean (SD) follow-up
20.4 (12.2) months





Figure 2. Cumulative probabilities of (A) any exacerbation, (B) moderate exacerbations, (C) severe exacerbations, and (D) survival during follow-up



- In the overall cohort (N=16,968), mean age was 63 years; 63% of patients were female, 68% were White, 44% had Medicare coverage, and 71% and 29%, respectively, were on dual and triple inhaled therapy.
- In patients with ≥2 moderate exacerbations during baseline (n=9209), the probabilities of moderate exacerbations (in Years 1, 2, and 3) were 0.64, 0.78, and 0.85, respectively; probabilities of severe exacerbations were 0.13, 0.22, and 0.30, respectively.
- In patients with ≥1 severe exacerbation during baseline (n=7759), the probabilities of moderate exacerbations (in Years 1, 2, and 3) were 0.47, 0.61, and 0.69, respectively; probabilities of severe exacerbations were 0.34, 0.48, and 0.56, respectively.
- 3-year mortality was higher among patients with severe exacerbations (27%) than moderate exacerbations (14%).

How might this impact current clinical practice?

- Patients who experienced exacerbations while receiving dual or triple inhaled therapy for COPD remain at significant risk of future exacerbations and mortality.**

- Innovative therapeutic approaches and targeted interventions are needed to reduce events and improve outcomes for this patient population, thereby alleviating the overall burden associated with COPD.**



E-poster



Supplementary material

Scan QR code to obtain a copy of these materials. Materials obtained through this QR code are for personal use only and may not be reproduced without permission from the authors of this poster.

Corresponding author email address: josefine.persson1@astrazeneca.com

Poster presented at ISPOR EU 2025; November 9-12, 2025; Glasgow, UK

Abbreviations
COPD, chronic obstructive pulmonary disease; DT, dual inhaled therapy; TT, triple inhaled therapy.

Acknowledgements

This study was sponsored by AstraZeneca. Medical writing was provided by Magdalene Michael, PhD, of Envision Value & Access, a part of Envision Medical Communications, funding for which was provided by AstraZeneca.

Disclosures

JP, MP, HD, and MF are employees of AstraZeneca and may hold stocks/shares. TLB is an employee of Optum Life Sciences. MCM reports NIH funding; royalties or licenses from UpToDate for authorship and editorial work for pulmonary function testing; consulting fees from Aribis, Boehringer Ingelheim, GSK, MCG Diagnostics, and NDD Medical Technologies; and payment or honoraria from Talem Health for medical education for asthma and COPD.